Analyses of the prognostic significance of the Epstein–Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma

Dardari, Rkia; Menezes, José; Drouet, Emmanuel; Joab, Irène; Benider, Abdellatif; Bakkali, H.; Kanouni, L.; Jouhadi, H.; Benjaafar, N.; Gueddari, B.K. El; Hassar, Mohammad; Khyatti, Meriem

doi:10.1016/j.jcv.2007.09.010

Cited by 16 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a more recent study, IgG-ZEBRA antibodies have been shown to represent a sensitive marker for the diagnosis of NPC in children than IgA-VCA and IgA-EA antibodies, which have been recognized as specific markers for this tumour. This study also indicates that Zp125, identified as the most immunogenic epitope of the activation domain of ZEBRA protein, showed a high degree of immunoreactivity with sera from children, young adult and older adult patients with NPC (Dardari et al 2008). The analysis of antibody patterns in patients with NPC indicates that IgG-ZEBRA had better prognostic value than IgA-EA and IgA-VCA.…”

Section: Prognostic Value Of Zebrasupporting

confidence: 56%

Role of the Epstein-Barr Virus ZEBRA Protein and HPV in the Carcinogenesis of Nasopharyngeal Carcinoma

Moumad¹,

Laantri²,

Mohammed³

et al. 2012

Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma

View full text Add to dashboard Cite

Section: Prognostic Value Of Zebrasupporting

confidence: 56%

Role of the Epstein-Barr Virus ZEBRA Protein and HPV in the Carcinogenesis of Nasopharyngeal Carcinoma

Moumad¹,

Laantri²,

Mohammed³

et al. 2012

Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma

View full text Add to dashboard Cite

“…Some reports indicate good IgM responses in mononucleosis patients, whereas others do not (Bravo et al 2009;Cameron et al 2010). IgA responses to Zta can be readily detected in NPC patients (Joab et al 1991;Dardari et al 2008). Three main epitopes have been mapped as immunodominant (Dardari et al 2008;Asito et al 2010).…”

Section: Ea(d)mentioning

confidence: 99%

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Middeldorp

2015

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is widely distributed in the world and associated with a still increasing number of acute, chronic, malignant and autoimmune disease syndromes. Humoral immune responses to EBV have been studied for diagnostic, pathogenic and protective (vaccine) purposes. These studies use a range of methodologies, from cell-based immunofluorescence testing to antibody-diversity analysis using immunoblot and epitope analysis using recombinant or synthetic peptide-scanning. First, the individual EBV antigen complexes (VCA , MA, EA(D), EA(R) and EBNA) are defined at cellular and molecular levels, providing a historic overview. The characteristic antibody responses to these complexes in health and disease are described, and differences are highlighted by clinical examples. Options for EBV vaccination are briefly addressed. For a selected number of immunodominant proteins, in particular EBNA1, the interaction with human antibodies is further detailed at the epitope level, revealing interesting insights for structure, function and immunological aspects, not considered previously. Humoral immune responses against EBV-encoded tumour antigens LMP1, LMP2 and BARF1 are addressed, which provide novel options for targeted immunotherapy. Finally, some considerations on EBV-linked autoimmune diseases are given, and mechanisms of antigen mimicry are briefly discussed. Further analysis of humoral immune responses against EBV in health and disease in carefully selected patient cohorts will open new options for understanding pathogenesis of individual EBV-linked diseases and developing targeted diagnostic and therapeutic approaches.

show abstract

“…Anti-EBV nuclear antigen-1 (EBNA1) antibodies are produced against EBNA1, the only antigen expressed in latently infected memory B cells and in eBL tumors (7). Anti-viral capsid antigen (anti-VCA), anti-early antigen (anti-EA), and anti-immediate-early protein (anti-Zta) antibodies are produced against their respective target lytic antigens (8). Clinically, elevated levels of anti-VCA and anti-EBNA1 immunoglobulin G (IgG) antibodies have been used as evidence of past infection (9), while the presence of IgG antibodies to the EBV early antigens (EAd and Zta) generally reflects recent or reactivated infections (10,11).…”

mentioning

confidence: 99%

Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy

Ogolla

Daud

Asito

et al. 2015

Clin Vaccine Immunol

View full text Add to dashboard Cite

h Over 35% of children in a region of malaria endemicity are infected with Epstein-Barr virus (EBV) by 6 months of age. This susceptibility may be linked to impaired transplacental transfer of antibodies. In this study, we determined the effect of malaria exposure during pregnancy on the transfer of EBV-specific maternal antibodies in a region of western Kenya that experiences endemic malaria. Pregnant mothers were recruited and followed up until delivery to determine levels of neonatal malaria exposure. Levels of EBV lytic (viral capsid antigen [VCA], Z transcriptional activator [Zta], and early diffuse antigen complex [EAd]) and EBV latent (EBV nuclear antigen-1 (EBNA1]) and tetanus-specific IgG antibodies were measured in 70 paired maternal and cord blood samples using a Luminex-bead-based assay. A high proportion (63%) of the infants were exposed to malaria in utero. Levels of EBV-and tetanus-specific antibodies were similar in malaria-infected mothers and in mothers who had no detectable malaria infection. Malaria-exposed neonates had significantly lower levels of anti-EBNA1, anti-Zta, and anti-EAd antibodies than were seen in their mothers. In utero malaria exposure resulted in significant reductions in transplacental transfer of anti-VCA-p18 and anti-EBNA1 antibodies of 13% and 22%, respectively. Neonates received significantly low levels of anti-Zta and anti-EAd antibodies irrespective of malaria exposure levels. In multivariate analysis, in utero malaria exposure was associated with a significant reduction in the transfer of anti-VCA-p18 and anti-EBNA1 antibodies to the neonates (P ‫؍‬ 0.0234 and P ‫؍‬ 0.0017, respectively). Malaria during pregnancy results in differential levels of transfer of EBV-specific antibodies from the mother to the fetus. The impaired transplacental transfer of some antibodies may lead to the malaria-exposed neonates being susceptible to early EBV infection. E ndemic Burkitt's lymphoma (eBL) is a distinct form of nonHodgkin's lymphoma and is the most common pediatric malignancy in regions of malaria endemicity of sub-Saharan Africa (1). Both infection with Epstein-Barr virus (EBV) and repeated episodes of Plasmodium falciparum malaria are known risk factors for eBL (2), but the mechanism(s) by which these two agents interact to promote the emergence of malignant B cell clones has not been elucidated. Recently, we found that infants from a region of malaria endemicity of western Kenya were infected with EBV by 6 months of age (3). Living in regions of malaria endemicity was a predictor of this early age of primary infection. This aberrant primary EBV infection may set the stage for lymphoma development, as previously hypothesized (4-6).The lytic and latent phases of the EBV life cycle induce distinct antibodies in response to specific lytic and latent antigens. Anti-EBV nuclear antigen-1 (EBNA1) antibodies are produced against EBNA1, the only antigen expressed in latently infected memory B cells and in eBL tumors (7). Anti-viral capsid antigen (anti-VCA), anti-early antigen (ant...

show abstract

Analyses of the prognostic significance of the Epstein–Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma

Cited by 16 publications

References 22 publications

Role of the Epstein-Barr Virus ZEBRA Protein and HPV in the Carcinogenesis of Nasopharyngeal Carcinoma

Role of the Epstein-Barr Virus ZEBRA Protein and HPV in the Carcinogenesis of Nasopharyngeal Carcinoma

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy

Contact Info

Product

Resources

About